Hydrochloric Acid → HCID 66863282, compound
Reaction equation
[CH3:1][S:2]([N:5]1[CH2:10][CH2:9][N:8]([C:11]2[CH:16]=[CH:15][C:14]([N:17]3[C:26]4[C:21](=[CH:22][CH:23]=[CH:24][CH:25]=4)[N:20](C(O)=O)[CH2:19][CH2:18]3)=[CH:13][CH:12]=2)[CH2:7][CH2:6]1)(=[O:4])=[O:3].Cl>ClCCl.O1CCOCC1>[CH3:1][S:2]([N:5]1[CH2:6][CH2:7][N:8]([C:11]2[CH:12]=[CH:13][C:14]([N:17]3[C:26]4[C:21](=[CH:22][CH:23]=[CH:24][CH:25]=4)[NH:20][CH2:19][CH2:18]3)=[CH:15][CH:16]=2)[CH2:9][CH2:10]1)(=[O:4])=[O:3]Participants
Procedure
31.5 g of the tert-butyl ester of 4-[4-(4-(methanesulphonyl)piperazin-1-yl)phenyl]-3,4-dihydro-2H-quinoxaline-1-carboxylic acid are placed in 400 ml of dichloromethane and then 333 ml of 4N hydrochloric acid in dioxane are added. After stirring for 16 h under an inert atmosphere, the solvents are evaporated under reduced pressure. Water, a saturated aqueous sodium hydrogencarbonate solution and dichloromethane are added. The aqueous sodium phase is extracted twice with dichloromethane. The organic phases are combined, washed with water and dried over magnesium sulphate and then the solvent is evaporated under reduced pressure. 23.2 g of 1-[4-(4-(methanesulphonyl)piperazin-1-yl)phenyl]-1,2,3,4-tetrahydroquinoxaline are obtained. The product is subsequently used as is without other purification.
Workup
- customthe solvents are evaporated under reduced pressure
- additionWater, a saturated aqueous sodium hydrogencarbonate solution and dichloromethane are added
- extractionThe aqueous sodium phase is extracted twice with dichloromethane
- washwashed with water
- dry with materialdried over magnesium sulphate
- customthe solvent is evaporated under reduced pressure
Sources & evidence
- ORD record
- ord-2ae001ada5f2421ab344445f73fa6188
- Source dataset
- uspto-grants-2013_09
- Patent number
- US08530657B2
Reaction notes
Loading…